The MBL Network companies are engaged in the research, development, manufacture, and sale of reagents for clinical examinations, gene tests, cytological diagnosis, and basic research on the basis of antibody development and manufacturing technology.
Moreover, the MBL Network also conducts research and development relating to new tumor markers, antibody drugs, immunology, and regenerative medicine, and participates, supports, and invests in the establishment and operation of bioventure companies.
In 1993, MBL established its U.S.-based subsidiary, MBL International Corporation (MBLI), in Boston as a company selling basic research reagents. MBLI has since expanded its sales channel and developed a worldwide business with its distributors in North America, South America, and Europe. In 2006, MBLI bought the antibody-related business of LifeSpan BioSciences, Inc., in Seattle.
In 2005, B&M was establised in China with the aim of selling MBL's products to all over the world.